Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7933807 | 1.00 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9ACA12 | |
| SCHEMBL7927546 | 1.00 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9ACA12 | |
| Hydrochloric Acid SCHEMBL6385217 | 0.98 | MEN1 (0.48) | MEN1KMT2ANPC1RAB9ACA12 | |
| Hydrochloric Acid SCHEMBL7933721 | 0.98 | MEN1 (0.48) | MEN1KMT2ANPC1RAB9ACA12 | |
| SCHEMBL4572446 | 0.89 | KMT2A (0.47) | MEN1KMT2ANPC1RAB9ACA12 | |
| SCHEMBL12493608 | 0.89 | KMT2A (0.47) | MEN1KMT2ANPC1RAB9ACA12 | |
| Hydrochloric Acid SCHEMBL7062680 | 0.87 | KMT2A (0.46) | MEN1KMT2ANPC1RAB9ACA12 | |
| SCHEMBL12493909 | 0.87 | KMT2A (0.46) | MEN1KMT2ANPC1RAB9ACA12 | |
| SCHEMBL12493905 | 0.87 | KMT2A (0.46) | MEN1KMT2ANPC1RAB9ACA12 | |
| SCHEMBL12493668 | 0.86 | MEN1 (0.44) | MEN1KMT2ANPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895535-B2 | Pyrrolidinones as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | claimed |
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | claimed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| CN-102203080-A | Heterocyclically substituted anilinopyrimidines as fungicides | BAYER CROPSCIENCE AG | 2011-09-28 | — | — | CN | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| EP-0959070-B1 | Process for the production of 3-amino-2-oxopyrrolidines, novel intermediates and their use | DEGUSSA (DE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1434485-B1 | NICOTINIC ACID-HETEROCYCLYL-AMIDES AND ANALOGOUS PYRIMIDINE DERIVATIVES FOR USE AS PESTICIDES | MERIAL LTD (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-0985665-B1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, intermediates and use thereof | DEGUSSA (DE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1147763-A1 | Oxidative dyeing composition for keratinic fibres containing 1-(4-aminophenyl)-pyrrolidine and an enzymatic oxidation system | L'OREAL (FR) | 2001-10-24 | — | — | EP | disclosed |
| US-6156908-A | Procedure for the manufacture of 3-amino-2-oxo-pyrrolidines, new intermediates and their use | ROHM GESELLSCHAFT, GMBH (DE) | 2000-12-05 | — | — | US | disclosed |
| EP-0985665-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, intermediates and use thereof | Degussa-Hüls Aktiengesellschaft (DE) | 2000-03-15 | — | — | EP | disclosed |
| EP-0959070-A1 | Process for the production of 3-amino-2-oxopyrrolidines, novel intermediates and their use | Degussa-Hüls Aktiengesellschaft (DE) | 1999-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | MEN1 2863/4885KMT2A 4375/4885NPC1 897/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | MEN1 2553/4885KMT2A 4677/4885NPC1 389/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | MEN1 2553/4885KMT2A 4677/4885NPC1 389/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | MEN1 4525/4885KMT2A 2698/4885NPC1 550/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | MEN1 2553/4885KMT2A 4677/4885NPC1 389/4885 |
| US-20130296274-A1 | PYRROLIDINONES AS METAP-2 INHIBITORS | METAP1, METAP2, DNPEP | MEN1 80/4885KMT2A 733/4885NPC1 4243/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | MEN1 2553/4885KMT2A 4677/4885NPC1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.